Effectiveness of lamivudine and interferon-? combination therapy versus interferon-? monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: A randomized clinical trial

Basit Öğe Kaydı
dc.authorid0000-0003-1514-1685
dc.authorid0000-0003-2005-0737
dc.contributor.authorKarabay, Oğuz
dc.contributor.authorTamer, Ali
dc.contributor.authorTahtaci, Mustafa
dc.contributor.authorVardi, Şeref
dc.contributor.authorÇelebi, Harika
dc.date.accessioned2021-06-23T18:54:26Z
dc.date.available2021-06-23T18:54:26Z
dc.date.issued2005
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractResults comparing the effectiveness of lamivudine used as monotherapy or in combination with interferon-alpha (IFN-?) in the treatment of chronic hepatitis B are not conclusive. This study compared the effects of IFN-? alone or in combination with lamivudine for the treatment of hepatitis B e antigen (HBeAg)-negative patients with chronic hepatitis B. Participation of patients in the IFN-? monotherapy and combination groups was randomized to a 1:1 ratio. Twenty seven HBeAg-negative patients with chronic hepatitis B received IFN-? (13 patients) at 9 million units 3 times weekly for 24 weeks or IFN-? at 9 million units 3 times weekly for 24 weeks plus lamivudine 100 mg/day (14 patients) daily for 1 year. Hepatitis B virus (HBV) DNA was measured quantitatively by real-time polymerase chain reaction at 0, 6, 12 and 18 months after the start of treatment. Sustained virologic response was defined as non-detectable serum HBV DNA 72 weeks after starting treatment. Sustained biochemical response was defined as normalization of alanine aminotransferase (ALT) values 72 weeks after starting treatment. The baseline characteristics of the 2 treatment groups were similar with respect to age, gender, ALT, HBV DNA levels and histologic diagnosis. Sustained biochemical responses were found at week 72 in 7 patients in each group (54% with IFN-? monotherapy and 50% with combination therapy) [p>0.05]. Sustained virologic responses were found at week 72 in 5 patients (38%) in the monotherapy and 7 patients (50%) in the combination therapy group (p>0.05). Combination therapy was not superior to IFN-? alone for the treatment of chronic hepatitis B. Combination treatment was associated with some disadvantages, such as additional cost. Lamivudine, on the other hand, may be more suitable for patients with cirrhosis, non-responders to IFN-? or in cases with contraindication for IFN-?.en_US
dc.identifier.endpage266en_US
dc.identifier.issn1684-1182
dc.identifier.issue4en_US
dc.identifier.pmid16118673en_US
dc.identifier.scopus2-s2.0-24744432107en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage262en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12491/4428
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-24744432107&partnerID=40&md5=36cd3b7dab3f5eca3bd825541a59cda5
dc.identifier.volume38en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKarabay, Oğuz
dc.institutionauthorTamer, Ali
dc.institutionauthorTahtaci, Mustafa
dc.institutionauthorVardi, Şeref
dc.institutionauthorÇelebi, Harika
dc.language.isoenen_US
dc.relation.ispartofJournal of Microbiology, Immunology and Infectionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCombination drug therapyen_US
dc.subjectHepatitis Ben_US
dc.subjectHepatitis B antibodiesen_US
dc.subjectInterferon-alphaen_US
dc.subjectLamivudineen_US
dc.titleEffectiveness of lamivudine and interferon-? combination therapy versus interferon-? monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: A randomized clinical trialen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu